Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03091491
Recruitment Status : Recruiting
First Posted : March 27, 2017
Last Update Posted : September 14, 2018
National University Hospital, Singapore
Johns Hopkins Singapore
Information provided by (Responsible Party):
National Cancer Centre, Singapore

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : June 2020